



DEC - 6 2001

PATENTIA POLICE

ATTORNEY 50 600 (2010): 045636-5037-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| For: | Peptide Epitopes Recognized by Antifilaggrin Autoantibodies in Serum From Rheumatoid Arthritis Patients |))) | |
|---------|---|-------------|----------------------|
| Filed: | June 30, 2000 |) | Examiner: L. Cook |
| Applic | ation No.: 09/582,711 |) | Group Art Unit: 1641 |
| ln re A | application of: G. SERRE et al. |) | |

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

RESPONSE TO RESTRICTION/ELECTION REQUIREMENT

In response to the Office Action mailed September 28, 2001 (Paper 12), Applicants respectfully elect, with traverse, Group A, claim(s) 1-12 drawn to compositions comprising sequence identification number 3 (SEQ ID 3) and its utility, classified in class 530, subclass 300 for example.

A petition for a two-month extension of time and a check in the amount of \$400.00 to cover the two-month extension of time fee accompany this Response.

In addition, Applicants respectfully request entry of the following amendments without prejudice.

IN THE CLAIMS:

Please amend claim 1 as indicated.

Please cancel claim 2.

1-WA/1709293.1

400_00 NP

12/04/2001 MGEBREM1 00000055 09582711





DEC _ 6 2001

TECH CENTER 1600/2900 PATENT ATTORNEY DOCKET NO.: 045636-5037

UNITED STATES PATENT AND TRADEMARK OFFICE

| In th | ne application of: |) |
|-------|--|-----------------------------|
| | G. SERRE et al. |)) |
| Seri | al No.: 09/582,711 |) Group Art Unit: 1641 |
| File | d: June 30, 2000 |) Examiner: L. COOK |
| For: | PEPTIDE EPITOPES RECOGNIZED BY ANTIFILAGGRIN AUTOANTIBODIES IN SERUM FROM RHEUMATOID ARTHRITIS PATIENTS |)))) |
| | istant Commissioner for Patents shington, D.C. 20231 | |
| RES | SPONSE TO ELECTION/RESTRICTION R | EQUIREMENT TRANSMITTAL FORM |
| | Transmitted herewith is a Response to Election/Frequirement in the Office Action mailed Septem | |
| | Additional papers enclosed: Drawings: Formal Informal (Corr Information Disclosure Statement Form PTO-1449, references included Citations Declaration of Biological Deposit | |
| | Submission of "Sequence Listing", computer thereto for biotechnology invention containing | |

ATTORNEY DOCKET NO.: 045636-5037

Serial No.: 09/582,711

Page 2

| | 3. | Extension | of Time |
|--|----|-----------|---------|
|--|----|-----------|---------|

The proceedings herein are for a patent application and the provisions of 37 CFR 1.136(a) apply.

- Applicants believe that no extension of time is required. However, this conditional petition is being made to provide for the possibility that applicants have inadvertently overlooked the need for a petition and fee for extension of time.
- Applicants petition for an extension of time, the fees for which are set out in 37 CFR 1.17(a)-(d), for the total number of months checked below:

| Total Months Requested | Fee for Extension | [fee for Small Entity] |
|--|--|--|
| □ one month ☑ two months □ three months □ four months | \$ 110.00 400.00 920.00 1,440.00 | \$ 55.00 200.00 460.00 720.00 |

- Extension of time fee due with this request: \$400.00
- If an additional extension of time is required, please consider this a Petition therefor.
- An extension for __months has already been secured and the fee paid therefor of \(\) is deducted from the total fee due for the total months of extension now requested.
- 4. **EXCEPT** for issue fees payable under 37 C.F.R. § 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§ 1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. § 1.136(a)(3).

ATTORNEY DOCKET NO.: 045636-5037

Serial No.: 09/582,711

Page 3

5. Fee Calculation

| CLAIMS AS AMENDED | | | | | | | |
|---|--|-------|-----------------------------|---------------|------------------|------|--------|
| | Claims Remaining After Response | | Highest No. Previously Paid | Present Extra | at Rate of | Tota | l Fees |
| Total Claims | 11 | minus | 12 | 0 | x \$18.00 each = | + \$ | 0.00 |
| Independent Claims | 1 | minus | 1 | 0 | x \$78.00 each = | + \$ | 0.00 |
| ☐ First presentation of Multiple dependent claim(s) \$ 260.00 | | | | | ≈ ∔ \$ | 0.00 | |
| SUB-TOTAL = | | | | | \$ | 0.00 | |
| Reduction by ½ for filing by a small entity | | | | | - \$ | 0.00 | |
| TOTAL FEE = | | | | | \$ | 0.00 | |

6. Fee Payment

- \square No fee is to be paid at this time.
- A check in the amount of \$400.00 for one-month extension of time is enclosed. The Commissioner is hereby authorized to charge any additional extension of time fee or additional fee for claims due to Deposit Account No. 50-0310.
- The Commissioner is hereby authorized to charge any fees including fees due under 37 CFR § 1.16 and § 1.17 which may be required, or credit any overpayment to Deposit Account 50-0310.

Respectfully submitted,

MORGAN, LEWIS & BOCKIUS

Dated: December 3, 2001

Elizabeth C. Weimar Reg. No. 44,478

CUSTOMER NO. 009629 MORGAN, LEWIS & BOCKIUS LLP 1800 M Street, N.W. Washington, D.C. 20036-5869 (202) 467-7000